Results 51 to 60 of about 286 (105)

Nirsevimab Administration and RSV Hospitalization in the 2024-2025 Season

JAMA Network Open
This cohort study examines rates of hospitalization associated with respiratory syncytial virus (RSV) among infants by nirsevimab administration during the 2024-2025 season.
Pelletier, Jonathan H., Rush, Sarah Z., Robinette, Eric, Maholtz, Danielle E., Bigham, Michael T., Forbes, Michael L., Shein, Steven L., Karsies, Todd J., Horvat, Christopher M.   +8 more
openaire   +2 more sources

Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis

Frontiers in Public Health
BackgroundRespiratory syncytial virus (RSV) causes lower respiratory tract infections (LRTIs) in infants, leading to substantial morbidity and mortality. Nirsevimab, a long-lasting monoclonal antibody, has been demonstrated to reduce RSV-related outcomes
Samira Soudani, Lorenzo Bertizzolo, Mehdi Ghemmouri, Mary Chappell, Rachael McCool, Katie Reddish, Paul Miller, Erin Barker, Harriet Fewster   +8 more
doaj   +1 more source

Nirsevimab Treatment of RSV Bronchiolitis in Pediatric Emergency Departments

JAMA Network Open
Importance New resistant mutations of respiratory syncytial virus type B (RSV-B) have been observed during the first year of implementation nirsevimab treatment. During the second season of implementation of nirsevimab treatment in France, RSV-B was predominant.
Lenglart, Lea, Levy, Corinne, Basmaci, Romain, Levieux, Karine, Kramer, Rolf, de Mari, Pauline, Béchet, Stéphane, Launay, Elise, Perceval, Lise, Cohen, Laure, Aupiais, Camille, de Pontual, Loic, Rybak, Alexis, Ouldali, Naim, Cohen, Robert   +14 more
openaire   +3 more sources

How a major discovery can become a public health failure when used subotptimally: lessons from early nirsevimab implementation

Italian Journal of Pediatrics
Background In this Debate, based on our clinical data from the “pre-nirsevimab” and “first year of nirsevimab implementation” bronchiolitis seasons, we challenge the validity of policy decisions that led to partial immunization coverage of eligible ...
Danilo Buonsenso, Aida Perramon-Malavez, Rosa Morello, Carolina Gentili, Marta Bellorofonte, Antoni Soriano-Arandes   +5 more
doaj   +1 more source

A single-center observational study of nirsevimab for prevention of RSV infection in preterm infants

Frontiers in Pediatrics
ObjectiveThis study aims to evaluate the clinical efficacy of nirsevimab in preventing respiratory syncytial virus (RSV) infection in preterm infants, highlighting its potential to improve neonatal respiratory health.MethodsWe conducted a retrospective ...
Rina Su, Rigonggaowa A, Fang Yao, Yanbin An, Cheng Cai, Lei Yun   +5 more
doaj   +1 more source

Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case–control study, Spain, 2023/24 season

Eurosurveillance
Background Respiratory syncytial virus (RSV) causes substantial morbidity in infants 
the Nirsevimab Effectiveness Study Collaborators
doaj   +1 more source

Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus

JAMA Network Open
IMPORTANCENirsevimab, a long-acting monoclonal antibody, demonstrated efficacy against respiratory syncytial virus (RSV)–associated lower respiratory tract infections (LRTI) in clinical trials. Postlicensure monitoring is essential to confirm these benefits in clinical settings.OBJECTIVETo estimate the effectiveness of nirsevimab against medically ...
Xu, Hanmeng, Aparicio, Camila, Wats, Aanchal, Araujo, Barbara L., Pitzer, Virginia E., Warren, Joshua L., Shapiro, Eugene D., Niccolai, Linda M., Weinberger, Daniel M., Oliveira, Carlos R.   +9 more
openaire   +2 more sources

Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants’ First RSV Season in the UK

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) poses a significant health burden on infants, particularly during their first RSV season. Immunoprophylactic strategies, such as the administration of nirsevimab, a long-acting monoclonal antibody, have been
Mersha Chetty, Paul Costello, Benjamin Yarnoff, Robert Musci, Mehdi Ghemmouri   +4 more
doaj   +1 more source

Two-season effectiveness of a single nirsevimab dose against RSV hospitalisation in healthy term-born infants: a population-based case–control study, Spain, October 2023 to March 2025

Eurosurveillance
BACKGROUND In autumn 2023, Spain recommended nirsevimab to all infants born after 1 April 2023, as catch-up or at-birth immunisation. AIM We estimated effectiveness of a single nirsevimab dose against respiratory syncytial virus (RSV) hospitalisations ...
the Nirsevimab Effectiveness Study Collaborators
doaj   +1 more source

The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study

Frontiers in Public Health
IntroductionRespiratory syncytial virus (RSV) infection is one of the main causes of morbidity and mortality from lower respiratory tract infections in children under 5 years of age worldwide.
José Francisco Barbas Del Buey, José Francisco Barbas Del Buey, Jesús Íñigo Martínez, María Ángeles Gutiérrez Rodríguez, Marcos Alonso García, Amaya Sánchez-Gómez, María Dolores Lasheras Carbajo, Susana Jiménez Bueno, María Dolores Esteban Vasallo, María Alejandra López Zambrano, Cristina Calvo Rey, Cristina Calvo Rey, Cristina Calvo Rey, Manuel Sanchez Luna, Manuel Sanchez Luna, Marta Molina Olivas, María Araceli Arce Arnáez   +16 more
doaj   +1 more source